BioSpace News Archive

Drug Development

Oncopeptides Sees Redemption with Positive Multiple Myeloma Data after ODAC Vote

One month after a contentious FDA advisory meeting, Oncopeptides announced positive data from the Phase III LIGHTHOUSE trial of Pepaxto in RRMM patients.

October 26, 2022
·
2 min read
·
Mark Terry
FDA

FDA Adcomm Returns Mixed Vote on GSK’s CKD Drug - Updated

An FDA adcomm that met Wednesday to vote on GlaxoSmithKline’s daprodustat for adult patients with anemia due to chronic kidney disease (CKD) produced mixed results.

October 26, 2022
·
3 min read
·
Mark Terry
VitroLabs Appoints Anthony Chow and Martin Avetisyan to its Board of Directors

VitroLabs Inc, the California based biotech company leading the commercialization of cell cultivated animal leather, announces the appointment of two new members to its Board of Directors

October 26, 2022
·
6 min read
Drug Development

J&J Maintains Momentum in Multiple Myeloma with Tecvayli Approval

The FDA has greenlit the use of Johnson & Johnson’s Tecvayli in heavily pretreated adult patients with relapsed or refractory multiple myeloma.

October 26, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Bridging the Translational Gap between Alzheimer’s Advances and Patients

With diagnostics for Alzheimer’s already approved and therapeutics in late-stage clinical trials, the next hurdle is to translate these advances into clinical practice. The Davos Alzheimer’s Collaborative is working on it.

October 26, 2022
·
7 min read
·
Gail Dutton
Drug Development

AstraZeneca Scores Double Win in Breast Cancer with Two Mid-Stage Candidates

AstraZeneca released data Wednesday morning from two studies in breast cancer: the Phase III CAPItello-291 trial studying capivasertib and the Phase II SERENA-2 trial studying camizestrant.

October 26, 2022
·
3 min read
·
Alex Keown
Drug Development

MS Drug Advances from Merck, BMS and More Showcased at ECTRIMS Conference

Merck, Bristol Myers Squibb, Biogen and others presented their latest data from MS programs at the 38th ECTRIMS conference.

October 26, 2022
·
2 min read
·
Kaley Lefevre
Policy

FDA’s ODAC Unanimously Votes against Y-mAbs’ Pediatric Neuroblastoma Treatment

The FDA’s Oncologic Drugs Advisory Committee voted unanimously against approving l-omburtamab for children with a rare form of neuroblastoma, citing complex review issues.

October 26, 2022
·
3 min read
·
Alex Keown and Heather McKenzie
Drug Development

TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma

TransCode Therapeutics, Inc., an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma.

October 26, 2022
·
6 min read
Policy

XORTX Receives Further No Objection Letter from Health Canada

XORTX Therapeutics Inc. is pleased to announce receipt of a further no objection letter from Health Canada regarding the Company’s ongoing XRX-OXY101 clinical bridging pharmacokinetics study.

October 26, 2022
·
5 min read